drugset / Trial / NCT07281976
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
Phase 1/2
Recruiting
220 enrolled
Nanjing Leads Biolabs Co.,Ltd
The First Affiliated Hospital with Nanjing Medical University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial is an open-label, multicenter phase Ib/II clinical study to evaluate the efficacy and safety of LBL-024 monotherapy or in combination with albumin-bound paclitaxel in patients with recurrent or metastatic triple negative breast cancer(TNBC).
Timeline
- Start
- 2026-01-27
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LBL-024 | Unknown | — | Intravenous |
| Subject | Paclitaxel | Small molecule | — | Intravenous |
| Comparator | Toripalimab | Monoclonal antibody | — | Intravenous |